Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
1,079,784,035
-
Number of holders
-
141
-
Total 13F shares, excl. options
-
46,154,939
-
Shares change
-
-3,800,832
-
Total reported value, excl. options
-
$83,993,343
-
Value change
-
-$34,886,181
-
Put/Call ratio
-
86%
-
Number of buys
-
69
-
Number of sells
-
-62
-
Price
-
$1.82
Significant Holders of ImmunityBio, Inc. - Common Stock, par value $0.0001 per share (IBRX) as of Q1 2023
177 filings reported holding IBRX - ImmunityBio, Inc. - Common Stock, par value $0.0001 per share as of Q1 2023.
ImmunityBio, Inc. - Common Stock, par value $0.0001 per share (IBRX) has 141 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 46,154,939 shares
of 1,079,784,035 outstanding shares and own 4.3% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (8,285,958 shares), BlackRock Inc. (6,965,519 shares), ARMISTICE CAPITAL, LLC (5,795,927 shares), STATE STREET CORP (2,649,813 shares), PICTET ASSET MANAGEMENT SA (2,421,900 shares), GEODE CAPITAL MANAGEMENT, LLC (1,945,864 shares), JPMORGAN CHASE & CO (1,613,297 shares), SHEETS SMITH WEALTH MANAGEMENT (1,590,398 shares), TANG CAPITAL MANAGEMENT LLC (1,095,795 shares), and CREDIT SUISSE AG/ (889,699 shares).
This table shows the top 141 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.